Episode 030: Dapagliflozin in Patients with Chronic Kidney Disease.
The Filtrate:
Matt Sparks
Joel Topf
Swapnil Hiremath
And two special guests:
Sue Quaggin Director, Feinberg Cardiovascular and Renal Research Institute. Chief of Nephrology and Hypertension in the Department of Medicine. Charles H. Mayo, MD, Professor of Medicine and Northwestern University. President of the American Society of Nephrology
Adeera Levin Professor of Medicine, Head Division of Nephrology at the University of British Columbia. Former president of the International Society of Nephrology
Show Notes:
NephJC coverage of DAPA-CKD
In the NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa2024816
NephMadness: https://ajkdblog.org
EMPEROR HF trial (went down to GFR 20 for enrolment) https://www.nejm.org/doi/full/10.1056/NEJMoa2022190
EMPA-KIDNEY Rationale https://pubmed.ncbi.nlm.nih.gov/30524708/ ; Link to protocol https://www.clinicaltrials.gov/ct2/show/NCT03594110 (also goes down to GFR 20, and includes non-diabetic and non-proteinuric patients)
NDT paper with baseline data and CKD etiology breakdown on DAPA-CKD https://academic.oup.com/ndt/article/35/10/1700/5899227
FDA gives breakthrough designation to Dapaglifozin in DM/nonDM CKD (based on press release)
Meta-analysis from Brendon Neuen et al, Flozin effect similar with/without background RAS blockade: https://pubmed.ncbi.nlm.nih.gov/31495651/
Are Flozins beta-blockers for the kidney https://pubmed.ncbi.nlm.nih.gov/27663956/
The Sotagliflozin trials
TOPCAT Spironolactone story https://www.nejm.org/doi/full/10.1056/nejmc1612601
Checkpoint now Podcast: https://checkpointnow.org/
Programming Note: After 30 episodes, Matt and Samira have their sea-legs and are moving on to new projects (hopefully including a new kidney podcast!) Swap, Jennie and I wish them luck. But don’t worry Freely Filtered is going to continue with the same format and some familiar voices who will join as new filtrates to rib Joel and keep Swap in line.